Consequently, it can enhance levels of kynurenine, immune checkpoint regulators (PD-L1 and B7-2), and epithelial–mesenchymal transition (EMT) regulators (Twist1 and Snail1) and thereby affect the survival time of patients with HCC (Wang et al. 2020b). Here, CD86 is linked to hepatocellular carcinoma.